Roche Holding (RHHBY) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Roche Holding (RHHBY)

57.26

-0.00 (0.00%)

as of Aug 7, 2026, 12:00:00 am Market Open.

12 watching

Investor Insights

Aug 11, 2026, 12:00 am

This summary was created by AI, based on 1 opinions in the last 12 months.

Roche Holding, symbol RHHBY-OTC, has recently received an upgrade, reflecting the confidence of experts in its performance and potential. The company has shown strong growth in the oncology sector and has reported a commendable 13% increase this year, signaling its robust market position. Investors are also attracted by the 3% dividend yield, which adds to its appeal as a steady income-generating asset. Currently, Roche is trading at a price-to-earnings (PE) ratio of 16x, suggesting that the stock is reasonably priced given its growth prospects. Overall, experts are optimistic about the trajectory of Roche Holding, making it an appealing choice for investors looking for growth coupled with dividends.

Consensus

Positive

Valuation

Fair Value

Similar

Novartis, NVS

Most recent Opinions go here

Be up to date, don't miss your chance.

BUY

Upgraded today. They're strong in oncology and overall. Is +13% this year. Pays a 3% dividend. Now trades at 16x PE. Great growth ahead.

Wealthica Track your Stocks in your Watch List

COMMENT

A month ago, they bought Carmot Therapeutics, a private clinical-stage biotech, though its drugs are only in phase 2 trials. Why did they buy this? So they can work on their own weight-loss drug, which are hot now.

BUY

Great company. Diagnostic businesses helped through Covid. Some of the pipeline is coming off patent. Used free cashflow to buy back shares and to buy a few businesses. This will be the macro trend: buy pipelines, because they can't R&D drugs fast enough. 15x earnings, yield is 3%, not expensive. Only problem might be having to buy it on a foreign exchange.

Premium content

It's a Monthly Gems opinion which is available only for Stockchase Premium

Curated by Allan Tong since 2019.
99+ opinions with 4.15 rating.

TOP PICK

The Swiss drugmaker has received FDA emergency approval to allow medical professionals to use its antibody test to determine if people have ever been infected with the virus. The test looks for antibodies in someone's blood that are used to fight off the virus that causes. Those exposed to Covid-19, even if they showed no symptoms, may have some immunity to it. The test would allow scientists to learn more about the disease, monitor how the Covid-19 is evolving, and help economies reopen. Roche plans to produce 60 million tests by the end of this month, while analysts expect the company to raise that to 100 million monthly by the end of the year. It looks like this news is already baked into the stock. Shares have returned to their mid-February peak, trading around $43-45. Roche Holding AG pays a 2.6% dividend with a forward PE of 13.69x. Revenue growth YOY stands at 5.48%.

PAST TOP PICK

(A Top Pick October 31/17 Up 10%) A steady business that pays a good dividend. You should make 10% a year return. There is a good pipeline of drug projects yet to come. Yield 3.5%

DON'T BUY

Made an acquisition quite a while ago of a biotech firm that comes up with all the future products. However, they are starting with some of the research that are in stage I and stage II. Sales were up 5% in the last quarter, but have seen a decline of 1% overall. The stock hasn't done a lot this year. Until this actually comes up with something that is going to be a gang buster, he would stay away.

TOP PICK

A Swiss company. Has been a laggard this year, and pulled back recently. Have some interesting drugs for multiple sclerosis, immunology on cancer. Trades 15%-20% cheaper than the rest of the pharmas. Dividend yield of 3.6%. (Analysts' price target is CHF 261.00)

PAST TOP PICK

(A Top Pick Oct 11/16. Down 2.05%.) A very deep pipeline of drugs and hidden value. It gives you a 3%+ yield. Great company.

TOP PICK

Deep pipeline. Attractively valued. It has a couple of drugs that are nearing approval in the 1^st half of this year. One is in the breast cancer area and one in the bio similar area. Dividend yield of 3.46%. (Analysts’ price target is CHF 278.65.)

BUY

or RHHBY-5. You can buy the ADR. They have a strong pipeline and can grow it. He thinks they will continue to do well. When do you buy them considering the US election? Pharma do not do well before a US election. You buy these things going into the election and you get a bounce out of them.

TOP PICK

Attractively valued at about 15X 2017 earnings. This has had 30 years of dividend growth. In addition to valuation, this has a very attractive pipeline with a hidden value of new products coming up. They also have a drug for multiple sclerosis that is due for regulatory action on December 28. Dividend yield of 3.39%.

DON'T BUY

They don’t have enough products in the pipeline. Many pharmas are struggling right now.

COMMENT

This is interesting right now based on the value proposition that is going into the pharma space. They have a lot of M&A activity there. This has some growth potential because of breast cancer. Fundamentally the company looks solid and the dividend looks good.

Showing 1 to 13 of 13 entries

Most Recent Experts

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Jim Lebenthal

Cerity Partners

Karen Firestone, CEO, Aureus Asset Management

Aureus Asset Management

Anastasia Amoroso, Chief investment strategist, iCapital

iCapital

Joe Terranova

Virtus Investment Partners

Roche Holding (RHHBY) Frequently Asked Questions

What is Roche Holding stock symbol?

Roche Holding is a American stock, trading under the symbol RHHBY (previously RHHBY-OTC on Stockchase) on the US OTC (RHHBY). It is usually referred to as OTC:RHHBY or RHHBY

Is Roche Holding a buy or a sell?

In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on RHHBY (previously RHHBY-OTC on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Roche Holding.

Is Roche Holding a good investment or a top pick?

Roche Holding was recommended as a Top Pick by Jenny Harrington, CEO, Gilman Hill Asset Management on 2026-08-07. Read the latest stock experts ratings for Roche Holding.

Why is Roche Holding stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Roche Holding.

Is Roche Holding worth watching?

Roche Holding is followed by 12 investors on Stockchase and is a trending stock that is worth watching.

What is Roche Holding stock price?

On 2026-08-07, Roche Holding (RHHBY) stock closed at a price of $57.26.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Roche Holding (RHHBY)

Most recent Opinions go here